Promising drug combo shows hope for slowing rare gut tumors

NCT ID NCT03972488

Ongoing Disease control Sponsor: Advanced Accelerator Applications Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding Lutathera to standard octreotide treatment can delay tumor growth in people with advanced neuroendocrine tumors of the stomach, intestines, or pancreas. The trial involved 226 patients with fast-growing tumors (grades 2 and 3) who had not received prior treatment. Results focus on how long the cancer stays under control and tumor shrinkage rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR

Contacts and locations

Locations

A.O.di Bologna Policl.S.Orsola

Bologna, Italy
Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology

Reggio Emilia, Italy
Asan Medical Center - Oncology

Seoul, South Korea
Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology

Roma, Italy
BC Cancer Agency

Vancouver, Canada
Bristol Haematology and Oncology Centre

Bristol, United Kingdom
CHU Paris Nord-Val de Seine

Clichy, France
CHU-Hôtel Dieu Service de Médecine Nucléaire

Nantes, France
Centre Hospitalier Universitaire de Quebec

Québec, Canada
Erasmus Medisch Centrum

Rotterdam, Netherlands
Fondazione Irccs Istituto Nazionale Tumori

Milan, Italy
Guys And St Thomas Hospital

London, United Kingdom
Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot

Lyon, France
Hospital General Universitario Gregorio Marañón

Madrid, Spain
Hospital Universitari i Politecnic La Fe

Valencia, Spain
Hospital Universitario Ramón y Cajal

Madrid, Spain
Hospital Universitario Vall d'Hebrón

Barcelona, Spain
IRCCS fondazione Pascale - Oncology

Naples, Italy
Ieo, Irccs

Milan, Italy
Institut Gustave Roussy

Villejuif, France
Institut du Cancer de Montpellier - Oncology

Montpellier, France
Istituto Oncologico Romagnolo

Meldola, Italy
Kings College Hospital - Oncology

London, United Kingdom
London Health Sciences Centre, University of Western Ontario - Oncology

London, Canada
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic - Oncology

Rochester, Minnesota, 55905, United States
Royal Free Hospital, London

London, United Kingdom
Seoul National University Bundang Hospital

Seongnam-si, South Korea
Seoul National University Hospital - Department of Internal Medicine

Seoul, South Korea
Severance Hospital, Yonsei University Health System - Medical Oncology

Seoul, South Korea
Sunnybrook Health Sciences Centre

Toronto, Canada
UMC Utrecht - Oncology

Utrecht, Netherlands
USF - H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
University of Genova - Oncology

Genova, Italy
University of Iowa Hospitals and Clinics - Oncology

Iowa City, Iowa, 52242, United States
University of Kentucky UK Markey Cancer Center

Lexington, Kentucky, 40536, United States
Universitätsklinikum Erlangen

Erlangen, Germany
Universitätsklinikum Essen - Klinik für Nuklearmedizin

Essen, Germany
Weston Park Hospital

Sheffield, United Kingdom
Yale Cancer Center

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.